BLICKENSTAFF KIM D
BLICKENSTAFF KIM D's purchase track record
BLICKENSTAFF KIM D has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/11/2024 | NUVB | $500K | +3.2% | -4.9% | +12.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Nuvation Bio Named In Penny Stock Watchlists. Nuvation Bio (NUVB) has been included in recent lists of penny stocks to watch for October 2026. The company's shares are currently trading near a key support level of $4.75, which has been tested multiple times. This technical position provides context for its inclusion in these speculative stock lists.
Transaction History
| TNDM | ▼ Sell | Open Market | 30,000 | $941K | 11/21/2024 | View on chart |
| TNDM | ▼ Sell | Open Market | 10,000 | $300K | 11/20/2024 | View on chart |
| NUVB | ▲ Buy | Open Market | 172,189 | $500K | 6/11/2024 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 4,434 | $229K | 5/24/2024 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 2,757 | $0 | 5/25/2023 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 2,205 | $0 | 5/18/2022 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 6,560 | $59K | 5/17/2022 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 13,562 | $1000K | 5/17/2022 | View on chart |
| TNDM | ▼ Sell | Open Market | 10,762 | $1000K | 5/17/2022 | View on chart |
| TNDM | ▼ Sell | Open Market | 28,400 | $3.2M | 9/2/2021 | View on chart |
| TNDM | ▼ Sell | Open Market | 300 | $34K | 9/2/2021 | View on chart |
| TNDM | ▲ Buy | Option Exercise | 28,700 | $100K | 8/27/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Barclays initiates coverage on Tandem Diabetes Care with Equal-Weight rating
Barclays has started covering Tandem Diabetes Care, assigning it an Equal-Weight rating and a price target of $18. This new analyst view comes as the company prepares to discuss its Q2 2026 earnings. The $18 target is at the lower end of the current analyst consensus range, which averages $27.86.
Barclays initiates coverage on Tandem Diabetes Care with Equal-Weight rating. Barclays has started covering Tandem Diabetes Care, assigning it an Equal-Weight rating and a price target of $18. This new analyst view comes as the company prepares to discuss its Q2 2026 earnings. The $18 target is at the lower end of the current analyst consensus range, which averages $27.86.